Product news from 09/09 News Brief

Share this article:

Takeda Pharmaceuticals North America announced that the FDA has approved the New Drug Application for ACTOplus Met for the treatment of type 2 diabetes.

Cephalon has entered into an agreement with McNeil Consumer & Specialty Pharmaceuticals to co-promote Attenace (modafinil) Tablets. Attenace is Cephalon's proprietary dosage form of modafinil, which is awaiting FDA approval for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. 

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union